Risk of BA.5 infection in individuals exposed to prior SARS-CoV-2 variants
Risk of BA.5 infection in individuals exposed to prior SARS-CoV-2 variants
Abstract The SARS-CoV-2 omicron BA.5 subvariant is progressively displacing earlier subvariants, BA.1 and BA.2, in many countries. One possible explanation is the ability of BA.5 to evade immune responses elicited by prior BA.1 and BA.2 infections. The impact of BA.1 infection on the risk of reinfection with BA.5 is a critical issue because adapted vaccines under current clinical development are based on BA.1. We used the national Portuguese COVID-19 registry to analyze the risk of BA.5 infection in individuals without a documented infection or previously infected during periods of distinct variants’ predominance (Wuhan-Hu-1, alpha, delta, BA.1/BA.2). National predominance periods were established according to the national SARS-CoV-2 genetic surveillance data (when one variant represented >90% of the sample isolates). We found that prior SARS-CoV-2 infection reduced the risk for BA.5 infection. The protection effectiveness, related to the uninfected group, for a first infection with Wuhan-Hu-1 was 52.9% (95% CI, 51.9 – 53.9%), for Alpha 54.9% (51.2 – 58.3%), for Delta 62.3% (61.4 – 63.3%), and for BA.1/BA.2 80.0% (79.7 – 80.2%). The results ought to be interpreted in the context of breakthrough infections within a population with a very high vaccine coverage (>98% of the study population completed the primary vaccination series). In conclusion, infection with BA.1/BA.2 reduces the risk for breakthrough infections with BA.5 in a highly vaccinated population. This finding is critical to appraise the current epidemiological situation and the development of adapted vaccines.
Malato Jo?o、Ribeiro Ruy M.、Fernandes Eug¨|nia、Graca Luis、Casaca Pedro、Antunes Carlos、Fonseca V¨￠lter R.、Leite Pedro Pinto、Gomes Manuel Carmo
Instituto de Medicina Molecular Jo?o Lobo Antunes, Faculdade de Medicina, Centro Acad¨|mico de Medicina de Lisboa, Universidade de Lisboa||CEAUL - Centro de Estat¨astica e Aplica??es da Universidade de LisboaInstituto de Medicina Molecular Jo?o Lobo Antunes, Faculdade de Medicina, Centro Acad¨|mico de Medicina de Lisboa, Universidade de Lisboa||Theoretical Biology and Biophysics, Los Alamos National LaboratoryDire??o de Servi?os de Informa??o e An¨￠lise, Dire??o Geral da Sa¨2deInstituto de Medicina Molecular Jo?o Lobo Antunes, Faculdade de Medicina, Centro Acad¨|mico de Medicina de Lisboa, Universidade de Lisboa||Comiss?o T¨|cnica de Vacina??o contra a COVID-19, Dire??o Geral de Sa¨2deDire??o de Servi?os de Informa??o e An¨￠lise, Dire??o Geral da Sa¨2deFaculdade de Ci¨oncias, Universidade de LisboaInstituto de Medicina Molecular Jo?o Lobo Antunes, Faculdade de Medicina, Centro Acad¨|mico de Medicina de Lisboa, Universidade de Lisboa||Comiss?o T¨|cnica de Vacina??o contra a COVID-19, Dire??o Geral de Sa¨2deDire??o de Servi?os de Informa??o e An¨￠lise, Dire??o Geral da Sa¨2deFaculdade de Ci¨oncias, Universidade de Lisboa||Comiss?o T¨|cnica de Vacina??o contra a COVID-19, Dire??o Geral de Sa¨2de
医药卫生理论医学研究方法预防医学
Malato Jo?o,Ribeiro Ruy M.,Fernandes Eug¨|nia,Graca Luis,Casaca Pedro,Antunes Carlos,Fonseca V¨￠lter R.,Leite Pedro Pinto,Gomes Manuel Carmo.Risk of BA.5 infection in individuals exposed to prior SARS-CoV-2 variants[EB/OL].(2025-03-28)[2025-05-28].https://www.medrxiv.org/content/10.1101/2022.07.27.22277602.点此复制
评论